Precigen's PAPZIMEOS approved, commercialization underway, patient hub enrollment surges.

Precigen has transitioned to a commercial stage company with the US approval of PAPZIMEOS, the first-and-only FDA-approved treatment for adults with RRP. Commercialization is underway, with 200 registered patients and significant demand from both major medical centers and community practices. Patient access is expanding, with private health plan coverage at approximately 170 million US lives, including Medicare and Medicaid. The European Medicines Agency has validated the Marketing Authorization Application for PAPZIMEOS. The company expects current capital resources to fund operations through cash flow break-even.